IMMUNITYBIO, INC. Paid-in-Kind Interest
IMMUNITYBIO, INC. (IBRX) reported Paid-in-Kind Interest of $9.19 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2024-03-19
- IMMUNITYBIO, INC. paid-in-kind interest for the quarter ending 2023-12-31 was $201.00K, a 93.75% decline year-over-year.
- IMMUNITYBIO, INC. paid-in-kind interest for the quarter ending 2023-09-30 was $3.96M, a 68.60% increase year-over-year.
- IMMUNITYBIO, INC. paid-in-kind interest for the quarter ending 2022-12-31 was $3.22M.
- IMMUNITYBIO, INC. paid-in-kind interest for the quarter ending 2022-09-30 was $2.35M.
- IMMUNITYBIO, INC. paid-in-kind interest for fiscal 2023 was $9.19M, a 21.77% decline from fiscal 2022.
- IMMUNITYBIO, INC. paid-in-kind interest for fiscal 2022 was $11.75M, a 5.40% decline from fiscal 2021.
- IMMUNITYBIO, INC. paid-in-kind interest for fiscal 2021 was $12.42M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2023-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.16M derived: sum of 2 quarters · filed 2024-03-19 | $9.19M 10-K · filed 2024-03-19 | |
| 2023-09-30 | $3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $8.99M 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $5.03M 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $5.57M derived: sum of 2 quarters · filed 2024-03-19 | $11.75M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $8.53M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $6.18M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $12.42M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |